- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ondansetron or metoclopramide, which is better for managing hyperemesis gravidarum?
Jordan: Ondansetron and metoclopramide seem to be equally effective for managing hyperemesis gravidarum (HG) among parturient females, says a study published in the Turkish Journal Of Obstetrics And Gynecology. However, due to the trending therapeutic efficacy and better safety profile of ondansetron, it is favored over metoclopramide.
Hyperemesis gravidarum is a pregnancy complication characterized by pernicious vomiting that affects various areas of the woman's health including electrolytes, homeostasis, and kidney function, and may have adverse fetal consequences.
Ebraheem Albazee, Faculty of Medicine, The Hashemite University, Zarqa, Jordan, and colleagues aimed to investigate the efficacy of ondansetron (intervention) versus metoclopramide (control) for treating parturient females with hyperemesis gravidarum.
For this purpose, the researchers polled data from randomized controlled trials (RCTs) using a meta-analysis approach. Five information sources were screened from inception until January 2022. Cochrane Risk of Bias (version 2) assessment tool was used for quality assessment. A total of five RCTs comprising a total of 695 patients (355 and 340 females were assigned to ondansetron and metoclopramide, respectively) were included.
Based on the meta-analysis, the researchers reported the following:
- Four RCTs had an overall "low" risk of bias, whereas one RCT had an overall "some concerns" due to a lack of sufficient information about randomization.
- There was no significant difference between both groups regarding the pregnancy-unique quantification of emesis and nausea score [MD=0.23], length of hospital stay [MD=-0.17 days], and the number of doses of drug received [MD=0.45], and duration of intravenous fluids [MD=-1.73 hours].
This led the authors to conclude, that "there was no substantial difference in efficacy between both agents, among parturient females with HG regarding all outcomes, including PUQE score, the number of doses of drug received, length of hospital stay, and duration of intravenous fluid treatment." "Nevertheless, ondansetron is favored over metoclopramide in view of its trending therapeutic efficacy and better safety profile."
Reference:
Albazee E, Almahmoud L, Al-Rshoud F, Sallam D, Albzea W, Alenezi R, Baradwan S, Abu-Zaid A. Ondansetron versus metoclopramide for managing hyperemesis gravidarum: A systematic review and meta-analysis of randomized controlled trials. Turk J Obstet Gynecol. 2022 Jun 27;19(2):162-169. doi: 10.4274/tjod.galenos.2022.14367. PMID: 35770443.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751